What You Should Know:

您应该知道：

– GoodRx, a prominent prescription savings platform in the U.S., has joined forces with ARS Pharmaceuticals to offer the lowest discounted cash price for neffy®, a revolutionary needle-free treatment for Type I allergic reactions.

–美国著名的处方储蓄平台GoodRx与ARS Pharmaceuticals联手，为neffy®提供最低折扣现金价格，neffy®是一种革命性的I型过敏反应无针治疗方法。

– The partnership makes neffy available for $199 at over 70,000 pharmacies across the nation, exclusively through GoodRx.

–该合作伙伴关系仅通过GoodRx在全国70000多家药店以199美元的价格提供neffy。

neffy: A Needle-Free Solution for Anaphylaxis

neffy：一种无针过敏反应溶液

Allergies and allergic reactions affect over 100 million Americans annually, with anaphylaxis posing a serious threat.  Approved by the FDA in August, neffy is the first needle-free treatment for anaphylaxis and other Type I allergic reactions, offering an alternative to traditional auto-injectors. By delivering epinephrine nasally, neffy eliminates the need for needle injections, a major hurdle for many, especially children and adults who require epinephrine..

过敏和过敏反应每年影响一亿多美国人，过敏反应构成严重威胁。8月，美国食品和药物管理局（FDA）批准了奈菲（neffy），它是第一种针对过敏反应和其他I型过敏反应的无针治疗药物，可替代传统的自动注射器。通过鼻内输送肾上腺素，neffy消除了针头注射的需要，这是许多人的主要障碍，尤其是需要肾上腺素的儿童和成人。。

GoodRx: Championing Innovation and Accessibility

GoodRx：支持创新和可访问性

GoodRx is dedicated to making essential medications more accessible and affordable while promoting innovation in healthcare. The company’s partnership with ARS Pharmaceuticals highlights this commitment, ensuring that neffy is available at a lower price, breaking down barriers to anaphylaxis treatment and offering a more convenient option for millions of Americans..

GoodRx致力于使基本药物更容易获得和负担得起，同时促进医疗保健创新。该公司与ARS Pharmaceuticals的合作突出了这一承诺，确保neffy以较低的价格上市，打破了过敏反应治疗的障碍，并为数百万美国人提供了更方便的选择。。

“We’re thrilled about neffy’s U.S. Food and Drug Administration approval, so people with severe allergies don’t have to endure needle-injection of epinephrine, which can be fraught with anxiety and fear, and can carry a device that’s small and effective. Through our partnership with GoodRx, we can offer our innovation in retail pharmacies along with patient programs to support its affordability,” said Richard Lowenthal, Co-Founder, President, and Chief Executive Officer of ARS Pharmaceuticals.

ARS Pharmaceuticals联合创始人、总裁兼首席执行官理查德·洛文塔尔（Richard Lowenthal）表示：“我们对内菲获得美国食品和药物管理局（FDA）的批准感到兴奋，因此严重过敏的人不必忍受肾上腺素的针头注射，肾上腺素可能充满焦虑和恐惧，并且可以携带小巧有效的设备。通过我们与GoodRx的合作，我们可以提供零售药店的创新以及患者计划，以支持其负担能力。”。

“We’re grateful that GoodRx’s platform has helped us reach more patients and caregivers to access a needle-free option so they can respond swiftly during a Type 1 allergic reaction.”.

“我们很感谢GoodRx的平台帮助我们接触到更多的患者和护理人员，让他们能够获得无针选项，以便他们在1型过敏反应期间迅速做出反应。”。

Consumers can access the savings on neffy at www.goodrx.com/neffy

消费者可以在www.goodrx.com/neffy上获得neffy的节省